Orthocell is a regenerative medicine company committed to improving the lives of patients suffering from serious musculoskeletal conditions by developing innovative products that restore patient mobility, function and performance. Orthocell is a publicly traded company listed on the Australian Securities Exchange (ASX:OCC). Orthocell’s two lead products are CelGro®, a superior collagen medical device that augments tissue repair and regeneration and Ortho-ATI®, the world leading cell therapy for treatment of chronic tendon injury.
CelGro® is approved for use in Europe (CE Mark) in a variety of dental bone and soft tissue regeneration procedures and has demonstrated superior clinical performance when compared to the current market leading product. Orthocell is focussed on Key Opinion Leader-Led market entry of CelGro® in Europe and is preparing for first approval in the US and Australia. CelGro® is a platform technology enabling Orthocell to accelerate the products use in other indications including bone, tendon, nerve and cartilage repair procedures in key markets.
Orthocell’s Ortho-ATI® is a first in class cell therapy for treatment of chronic tendon injuries. Ortho-ATI® addresses a significant unmet clinical need for a safe, effective and non-surgical solution for a debilitating injury affecting millions of people every year. The unique treatment uses each patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via ultrasound guided injection under local anaesthetic. Orthocell is delighted to be undertaking its research collaboration with Johnson and Johnson, designed to assess the safety and effectiveness of Ortho-ATI® in the treatment of rotator cuff tendinopathy and tear. Orthocell is focussed on completing clinical studies and driving the technology into the US, the world’s largest health care market.